



## **"The Pivotal Role of Toxoid Vaccines in Modern Public Health: History, Mechanisms, and Future Prospects"**

***Miss.Mayuri G. Zore <sup>a</sup>, Mr.Shivshankar M.Nagrik <sup>b</sup>, Mr.Mangesh M. Girhe <sup>c</sup>,Mr.Prajwal R. Ambalkar<sup>d</sup>, Mr.Dnyaneshwar R. Bajad <sup>e</sup>, Miss.Prajakta S. Ghonge<sup>f</sup>, Miss. Aachal V. Ingle <sup>g</sup>***

<sup>a</sup>Asst. Prof. Department of Pharmacy, GCP, Sakharkherda, Buldhana, 443202,India.

<sup>b</sup>Student.M.Pharm, Department of Pharmaceutics, RSCP, Buldhana, 443202,India

<sup>c</sup>,Asst. Prof. Department of Pharmacy, LRZ, Kenwad, Washim, 444503,India.

<sup>d</sup>Student, B. Pharm, ACP,Chikhali, Buldhana , 411062,India .

<sup>e,g</sup> Student, B. Pharm, GCP, Sakharkherda, Buldhana ,443202,India .

### **ABSTRACT :**

Vaccination is a cornerstone of public health, significantly reducing mortality and morbidity from infectious diseases. Toxoid vaccines, which target bacterial toxins rather than the bacteria themselves, play a crucial role among various vaccine types. These vaccines are developed by detoxifying bacterial toxins, rendering them non-harmful yet capable of inducing an immune response. This review examines the fundamentals, advancements, and applications of toxoid vaccines, with a focus on their continued relevance and efficacy. Toxoid vaccines, first pioneered by Emil von Behring and Shibasaburo Kitasato in the early 20th century, have been instrumental in combating diseases like diphtheria and tetanus. These vaccines are integral to modern immunization programs, often combined with other vaccine components to enhance disease prevention. Recent innovations, such as nanotoxoids and the use of micro/nano-carriers, have further improved vaccine delivery and efficacy. The safety and immunogenicity of toxoid vaccines are well-documented, with booster shots recommended to maintain immunity. Notably, toxoid vaccines for pathogens like *Staphylococcus aureus* and Enterohemorrhagic *Escherichia coli* are under development, targeting specific virulence factors. Raman spectroscopy has emerged as a valuable tool for vaccine quality control, enhancing the reliability of manufacturing processes. Despite their age, toxoid vaccines remain highly effective and continue to evolve. They represent a successful translation of scientific research into public health practice, offering protection against toxin-mediated diseases and contributing to global health security. This review underscores the importance of toxoid vaccines in the broader context of vaccine development and infectious disease prevention.

**Keywords:** Toxoid Vaccines, Bacterial Toxins Neutralization, Diphtheria, Combined Vaccines, *Staphylococcus aureus*, ultravalent Toxoid Vaccines.

### **1. Introduction :**

Vaccination has remained to be one of the great achievements of public health, as a result of which the loss of lives and the overall strain that infectious diseases have put to the world has been checked to a great extent. This feature gives toxoid vaccines a crucial role among the existent types, aimed at neutralising the effects of bacterial toxins[1]. Toxoid vaccines can be described as vaccines that prompt a reaction aimed at the specific toxin that is associated with bacteria and not the bacteria per se. To start with, the first section outlines the fundamentals, advancement, and application of toxoid vaccines in today's practice. Toxoid vaccines are developed through the process of detoxifying the toxin; this makes the toxin non-harmful, however, the toxin is still capable of initiating an immune response[2]. The latter can be done chemically by, for example, exposure to formaldehyde or by heat treatment. The toxin is inactivated so as to reduce its toxicity in the process, but it still retains its ability to stimulate an immune response in the body that would protect against the actual toxin in case it is encountered again. This approach has been particularly successful in vaccines against diseases such as diphtheria and tetanus, in which the syndromes are produced by the toxins which are released by the bacteria but of no additional bacterial contamination. Toxoid vaccines have therefore been in development or some time now with pioneers in this field being Emil von Behring, and Shibasaburo Kitasato at the early of the twentieth century[3].

They conducted initial work on diphtheria antitoxin which eventually used in the development of toxoid vaccines that has contributed a great deal in lessening the near fatal diseases like diphtheria and tetanus. To this date, toxoid vaccines are still widely used in immunization programs in the modern context of the medical practice. Some components, often the more dangerous ones, are incorporated into a range of combined vaccines, say DTaP (diphtheria, tetanus, acellular pertussis) – meaning a number of diseases can be fought using one shot[4]. Therefore, toxoid vaccines can be regarded sufficient, as extensive use of these vaccines shows their importance in preventing infectious diseases. As we step forward in this new generation of more advanced forms of vaccines, the basics of toxoid vaccines have not been rendered obsolete. These studies signify the significance of learning about the mechanisms of microbial infection and host defense, realizing insights wonderful for the formulation of brand new and even enhanced vaccines[5].

Altogether, toxoid vaccines can be properly described as an excellent example of how scientific advancement can be fruitfully translated into the sphere of public health and, in general, remain highly relevant to this day so that vaccination continues to remain a key method of protecting human lives. Toxoid vaccines are a promising approach in vaccine development, especially in combating infections caused by pathogens like *Staphylococcus aureus* (SA) [6]. These vaccines target virulence factors, such as leukotoxins, to prevent mortality and morbidity associated with infections. Nanotoxoids, created by complexing toxins with cell membrane-coated nanoparticles, offer a novel strategy for safe and effective vaccine delivery, generating strong immune responses [7]. Research has shown that a combination of antibodies against different superantigens can provide broad neutralization of staphylococcal SAGs, supporting the development of multivalent toxoid vaccines against SA infections [8]. Furthermore, studies on tetanus toxoid, diphtheria toxoid, and acellular pertussis booster vaccines have demonstrated the safety, immunogenicity, and non-inferiority of these toxoid formulations, highlighting their potential in preventing infectious diseases [9]. Raman spectroscopy has also emerged as a valuable tool for the identification and differentiation of vaccine products, offering fast and reliable quality control measures in vaccine manufacturing processes [10].

Toxoid vaccines, as described in the provided research papers, consist of non-disrupted or non-denatured toxins associated with a particulate vector to prevent toxin-induced damage [11]. These vaccines target virulence factors of pathogens like *Staphylococcus aureus* (SA) by focusing on toxins such as alpha hemolysin, Panton-Valentine leukocidin, leukocidin AB, toxic shock syndrome toxin-1, and staphylococcal enterotoxins A and B [12]. The development of toxoid vaccines involves generating attenuated toxoids through mutagenesis to elicit high neutralizing antibody titers against toxins like LukAB, which is present in all SA clinical isolates [13]. Additionally, toxoid vaccines for Enterohemorrhagic *Escherichia coli* (EHEC) include inactivated Shiga toxins produced from specific EHEC strains to prevent infections in cattle [14]. Recent advancements in vaccine delivery systems utilize micro/nano-carriers to enhance vaccination coverage and reduce costs by delivering toxoid antigens effectively [15].

---

## 2. Vaccine Types

### • Inactivated vaccine

- Hepatitis A
- Flu
- Polio
- Rabies

### • Live-attenuated vaccine

- Measles, mumps, rubella [MMR combine vaccine]
- Rotavirus
- smallpox
- chickenpox
- yellow fever

### • Messenger RNA [mRNA vaccine]

- COVID-19
- Toxoid vaccines

### *Tetanus*

Muscle spasms that linger for many minutes at a time can occur all over the body as a result of tetanus, which is brought on by *Clostridium tetani*. Although most people can recover on their own over several months, 10% of cases who are not vaccinated result in death. Tetanus vaccinations have significantly reduced both the fatality rate and the number of cases globally (up to 95%). Nowadays, people who are either not inoculated or have received insufficient immunizations account for the majority of tetanus infections. Because of the tetanus toxin's strength, exposure to and recovery from natural toxins do not produce natural immunity, in contrast to most other toxins and infections [16]. On the other hand, tetanus toxoid (TT) vaccination exposure produces a strong immune memory. This vaccination is safe and effective, but as many as 25–85% of individuals may experience localized inflammation (pain and redness) at the injection site; serious allergic reactions are incredibly rare. The key thing to remember about toxoids is that, even if they can no longer harm the body, they nevertheless have a crucial characteristic known as "immunogenicity." This essentially indicates that the body still perceives them as hazardous, which triggers an immune response that primes the body for infection and further exposure to the original toxin [17].

### *Diphtheria*

The symptoms of diphtheria (which is caused by the bacteria *Corynebacterium diphtheriae*) include fever, enlarged glands, and a thick layer of gray-white material at the back of the throat. It can result in big blisters or ulcers filled with pus if it gets into the skin, which can happen through cuts or wounds. A raised bump at the injection site that may persist for many weeks is the only common side effect of the diphtheria vaccination, which has led to a 90% reduction in cases globally. A combination vaccine is used to immunize against both tetanus and diphtheria [18].

***What is a Toxoid?***

Poisons lead to serious illnesses. Researchers have endeavored to devise strategies to combat pollutants. These experiments have allowed them to create weapons known as toxoids. A toxoid is a weakened or inactivated toxin. Toxoids combat other poisons[19]. Toxoids are safe vaccines designed to treat diseases caused by toxins. The toxoid loses the toxin's harmful properties. Toxoid's structure, however, is comparable to that of its parent toxin. However, the toxoid does not hold on to the toxicity any longer[20]. The toxoid retains the toxin's immunogenic properties, which stimulate the host's immune system. Toxoid composition is changed to eliminate adverse effects. Proper heating of the poisons modifies their characteristics. The toxins are not organic. Although derived from primordial poisons, they are man-made. Toxoids are created as vaccines and administered to humans and animals to build immunity against illnesses based on toxins[21].

**Fig.1*****How do toxoid vaccines work?***

The body is harmed by various microbes in different ways and by diverse methods. Some bacteria release strong compounds known as to carry out their damaging effects. These poisons cause physiological disruptions that ultimately lead to illness[22].

**3.Classification of toxoid**

TOXIN	ORGANISM	TOXOID
Tetanus toxin	Clostridium Tetani	Tetanus toxoid
Diphtheria toxin	Corynebacterium diphtheriae	Diphtheria toxoid
Botulinum toxin	Clostridium botulinum	Botulinum toxoid
Pertussis toxin	Bordetella pertussis	Bordetella pertussis toxoid antigen"[7] (see pertussis vaccine)
Tracheal cytotoxin	Bordetella pertussis	
Erythrogenic toxin	Streptococcus pyogenes	
Leukocidin, Streptolysins	Streptococcus pyogenes	
Clostridial a- toxin	Clostridial perfringens	
Cholera toxin	Vibrio cholerae	(Used in experimental TA-CD)
Anthrax toxin	Bacillus anthracis	See anthrax vaccines
Pertussis toxin	Bordetella pertussis	"Bordetella pertussis toxoid antigen" (see pertussis vaccine)
Tracheal cytotoxin	Bordetella pertussis	
Cholera toxin	Vibrio cholerae	Used in experimental TA-CD
Leukocidin, Streptolysins	Streptococcus pyogenes	
Anthrax toxin	Bacillus anthracis	(see anthrax vaccines)

## 4. History




Fig.2

The first vaccination was created in 1796 by British physician Edward Jenner, who protected people against smallpox, a similar virus, by using the cowpox virus (vaccinia). But before that, Asian doctors used the concept of vaccination to prevent smallpox in children by giving them dried crusts made from the lesions of afflicted patients. Some people acquired immunity, while others became ill[23].

Jenner's contribution was the use of an immunity-granting agent akin to smallpox but less dangerous. He took use of the comparatively uncommon circumstance where immunity to one virus provides defense against another viral-related illness. By injecting attenuated versions of the bacillus that causes anthrax into sheep, French microbiologist Louis Pasteur proved that people could be immune to the disease in 1881. He developed a rabies protective suspension four years later[24].




Fig.3

Following Pasteur's work, a broad and comprehensive search was carried out to find additional vaccines. As a result, vaccinations against venoms and other toxins, as well as vaccines against bacteria and viruses, were created. By 1980, smallpox had been eliminated globally through vaccination, and the number of cases of polio had fallen by 99 percent[25]. The mumps, measles, typhoid fever, cholera, plague, tuberculosis, tularemia, pneumococcal infection, tetanus, influenza, yellow fever, hepatitis A, hepatitis B, some types of encephalitis, and typhus are other illnesses for which vaccines have been developed; however, some of those vaccines are not 100% effective or are only administered to populations who are at high risk. Since viral illnesses do not react to antibiotics, in contrast to bacterial infections, vaccinations against viruses offer particularly significant immunological protection[26].

## 5. Advantages and Disadvantages

### Advantage:

- The exotoxin is immunogenic and whole organism can be avoided.
- They are used to prevent original toxin activity in a body.
- They develop memory in a body after first injected.

- Toxoid vaccines are especially good at preventing certain toxin-mediated diseases such as tetanus, diphtheria, and pertussis. Booster shots are typically recommended every 10 years or so.

**Disadvantage:**

- Only effective if diseases caused solely by bacterial exotoxins
- They did not cause any disease as well but some time can cause side effects to mount immune system.
- Even with the adjuvant, these vaccines do not produce a full immune response. Booster shots are needed to maintain the immunity.

---

## 6. Dosage

Usual Adult Dose for Tetanus Prophylaxis Primary Immunization - Series of three doses:

0.5 mL IM of tetanus toxoid adsorbed once, followed by a second dose 4 to 8 weeks later, and the third dose given 6 to 12 months after the second dose.

Routine Booster injection

0.5 mL IM of tetanus toxoid adsorbed or 0.5 mL IM or subcutaneously of tetanus toxoid given 10 years after completion of primary immunization and every 10 years thereafter. If a dose is given sooner as part of wound management, the next booster is not needed for 10 years thereafter.

Usual Pediatric Dose for Tetanus Prophylaxis  $\geq 7$  years[27].

Primary Immunization - Series of three doses:

0.5 mL IM of tetanus toxoid adsorbed once, followed by a second dose 4 to 8 weeks later, and the third dose given 6 to 12 months after the second dose.

### Dose Adjustments

Children older than 7 years who did not complete primary immunization series (e.g., previously received only two doses of DTaP or DTP) need to receive only one dose of tetanus toxoid adsorbed vaccine to complete the primary series of tetanus.

Booster injection after injury ( $\geq 7$  years):

- If primary immunization confirmed and the wound is clean and minor: no need for injection.
- If unknown or uncertain prior immunization (or less than 3 doses) in clean, minor wound: 0.5 mL IM.
- All other dirty wounds (contaminated with feces, soil, and saliva): 0.5 mL IM along with tetanus immune globulin. The next booster dose not needed for 10 years thereafter[28].

---

## 7. Side effects

### Tetanus toxoid

Applies to tetanus toxoid: intramuscular solution, intramuscular suspension.

- **Cardiovascular**

Cardiovascular side effects have included hypotension.

- **Dermatologic**

Dermatologic side effects have included redness, warmth, edema, induration with or without tenderness as well as urticaria, and rash.

- **Hypersensitivity**

Hypersensitivity side effects have rarely included an anaphylactic reaction (i.e., hives, swelling of the mouth, difficulty breathing, hypotension, or shock) following administration of products containing tetanus toxoid. Arthus-type hypersensitivity reactions, characterized by severe local reactions (generally starting 2 to 8 hours after injection) may occur, particularly in persons who have received multiple prior boosters. Deaths have been reported in temporal association with the administration of tetanus toxoid containing vaccines[29].

- **General**

General side effects have included malaise, transient fever, pain, hypotension, nausea and arthralgia in some patients following an injection[30]. Side effects observed following immunization with vaccines should be reported by healthcare providers to the US Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS). Reporting forms and information about reporting requirements or completion of the form can be obtained from VAERS through a toll-free number 1-800-822-7967.

Healthcare providers also should report these events to the Pharmacovigilance Department, Aventis Pasteur Inc., Discovery Drive, Swiftwater, PA 18370 or call 1-800-822-2463.

- **Nervous system**

Nervous system side effects have included neurological complications including cochlear lesion, brachial plexus neuropathies, paralysis of the radial nerve, paralysis of the recurrent nerve, accommodation paresis, Guillain-Barre syndrome, and EEG disturbances with encephalopathy[31].

## 8.Toxoid vaccines available in market

Brand name	Composition	Company	Packing
Bett inj	tetanus toxoid > 5 lf to < 25 lf per 0.5ml	biological e.	0.5ml
Bett inj	tetanus toxoid > 5 lf to ≤ 25 lf per 0.5ml	biological e.	5ml
Tetanus antitoxin inj	tetanus antitoxin 750 iu 1500 iu ,10000 iu, 20000 iu, 50000 iu,	biological immunity	1 amp
Tetanus antitoxin inj	tetanus antitoxin 750 iu, 1000 iu	biological e.	1 amp
Tetanus toxoid adsorbed inj	tetanus toxoid> 5 lf to < 25 lf per 0.5ml	serum institute	10amp
Tetanus toxoid adsorbed inj	tetanus toxoid> 5 lf to < 25 lf per 0.5ml	serum institute	5ml vial
Tetanus toxoid inj	tetanus toxoid> 5 lf to < 25 lf per 0.5ml	biological e.	0.5ml amp
Tetanus toxoid inj	tetanus toxoid> 5 lf to < 25 lf per 0.5ml	biological e.	5ml vial
Tetanus toxoid inj	tetanus toxoid> 5 lf to < 25 lf per 0.5ml	haffkine	10 amp
Tetanus toxoid inj	tetanus toxoid> 5 lf to < 25 lf per 0.5ml	haffkine	vial

## Conclusion

Vaccination stands as one of the most significant triumphs of public health, dramatically reducing the mortality and morbidity associated with infectious diseases. Among the various vaccine types, toxoid vaccines hold a special place due to their targeted approach in neutralizing bacterial toxins, rather than the bacteria themselves. This characteristic underlines their crucial role in immunization strategies against toxin-mediated diseases such as diphtheria and tetanus. Toxoid vaccines are crafted by detoxifying bacterial toxins, rendering them non-harmful while preserving their ability to elicit an immune response. This method has proved particularly effective, providing robust protection against diseases where bacterial toxins play a pivotal role in pathogenesis. Historically, the pioneering work of Emil von Behring and Shibasaburo Kitasato in the early 20th century laid the foundation for the development of these vaccines, which have since remained integral to global immunization programs.

Contemporary advancements continue to enhance the efficacy and safety of toxoid vaccines. Innovations such as nanotoxoids and multivalent formulations against pathogens like *Staphylococcus aureus* exemplify the ongoing evolution in this field. These advancements not only reinforce the relevance of toxoid vaccines but also demonstrate their adaptability in addressing emerging health threats. Moreover, the integration of toxoid vaccines into combined immunization schedules, such as the DTaP vaccine, highlights their versatility and efficiency in providing comprehensive protection against multiple diseases with a single injection. This approach not only improves vaccination coverage but also optimizes healthcare resources. The future of vaccine development promises even more sophisticated strategies, yet the foundational principles of toxoid vaccines will remain invaluable. These vaccines exemplify the successful translation of scientific research into practical public health solutions, continuing to protect countless lives worldwide. The enduring relevance of toxoid vaccines underscores the importance of ongoing research and innovation in the quest to combat infectious diseases and safeguard public health.

## REFERENCES :

1. Trollfors B, Taranger J, Lagergård T, Lind L, Sundh V, Zackrisson G, Lowe CU, Blackwelder W, Robbins JB. A placebo-controlled trial of a pertussis-toxoid vaccine. *New England Journal of Medicine*. 1995 Oct 19;333(16):1045-50.

2. Donald RG, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, Matsuka YV. A novel approach to generate a recombinant toxoid vaccine against *Clostridium difficile*. *Microbiology*. 2013 Jul;159(Pt\_7):1254-66.
3. Kotloff KL, Wasserman SS, Losonsky GA, Thomas Jr W, Nichols R, Edelman R, Bridwell M, Monath TP. Safety and immunogenicity of increasing doses of a *Clostridium difficile* toxoid vaccine administered to healthy adults. *Infection and immunity*. 2001 Feb 1;69(2):988-95.
4. Schneerson R, Robbins JB, Taranger J, Lagergard T, Trollfors B. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. *The Lancet*. 1996 Nov 9;348(9037):1289-92.
5. Hviid A, Stellfeld M, Andersen PH, Wohlfahrt J, Melbye M. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. *Vaccine*. 2004 Sep 9;22(27-28):3530-4.
6. Guo Z, Kubiatowicz LJ, Fang RH, Zhang L. Nanotoxoids: Biomimetic Nanoparticle Vaccines against Infections. *Advanced Therapeutics* 2021;4. <https://doi.org/10.1002/adtp.202100072>.
7. Kailasan S, Kort T, Mukherjee I, Liao GC, Kanipakala T, Williston N, et al. Rational Design of Toxoid Vaccine Candidates for *Staphylococcus aureus* Leukocidin AB (LukAB). *Toxins* 2019;11:339. <https://doi.org/10.3390/toxins11060339>.
8. Sharma HJ, Parekh S, Pujari P, Shewale S, Desai S, Kawade A, et al. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India. *Expert Review of Vaccines* 2023;22:278-87. <https://doi.org/10.1080/14760584.2023.2188942>.
9. Venkatasubramaniam A, Adhikari RP, Kort T, Liao GC, Conley S, Abaandou L, et al. TBA225, a fusion toxoid vaccine for protection and broad neutralization of staphylococcal superantigens. *Scientific Reports* 2019;9. <https://doi.org/10.1038/s41598-019-39890-z>.
10. Silge A, Bocklitz T, Becker B, Matheis W, Popp J, Bekeredjian-Ding I. Raman spectroscopy-based identification of toxoid vaccine products. *Npj Vaccines* 2018;3. <https://doi.org/10.1038/s41541-018-0088-y>.
11. Karazum H, Venkatasubramaniam A, Adhikari RP, Kort T, Holtsberg FW, Mukherjee I, et al. IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by *Staphylococcus aureus*. *Frontiers in Immunology* 2021;12. <https://doi.org/10.3389/fimmu.2021.624310>.
12. Kailasan S, Kort T, Mukherjee I, Liao GC, Kanipakala T, Williston N, et al. Rational Design of Toxoid Vaccine Candidates for *Staphylococcus aureus* Leukocidin AB (LukAB). *Toxins* 2019b;11:339. <https://doi.org/10.3390/toxins11060339>.
13. Taxt AM, Diaz Y, Aasland R, Clements JD, Nataro JP, Sommerfelt H, Puntervoll P. Towards rational design of a toxoid vaccine against the heat-stable toxin of *Escherichia coli*. *Infection and immunity*. 2016 Apr;84(4):1239-49.
14. Taranger J, Trollfors B, Bergfors E, Knutsson N, Lagergard T, Schneerson R, Robbins JB. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. *Pediatrics*. 2001 Dec 1;108(6):e115-.
15. Park G-Y, Ahn G, Lee SH, Kim SB, Kim Y-H, Ahn J-Y. Efficient Delivery of Toxoid Antigens using Micro/Nano-carriers 2018;28:496-507. <https://doi.org/10.5352/jls.2018.28.4.496>.
16. Blencowe H, Lawn J, Vandelaer J, Roper M, Cousens S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. *International journal of epidemiology*. 2010 Apr 1;39(suppl\_1):i102-9.
17. Dietz V, Milstien JB, Van Loon F, Cochi S, Bennett J. Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus. *Bulletin of the World Health Organization*. 1996;74(6):619.
18. Kretsinger K, Broder KR, Cortese MM, Joyce P, Ortega-Sanchez I, Lee GM, Tiwari T, Cohn AC, Slade BA, Iskander JK, Mijalski CM. Preventing tetanus, diphtheria, and pertussis among adults; use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
19. Spotnitz H. The toxoid response. *Psychoanalytic review*. 1963 Dec 1;50(4):81.
20. Trollfors B, Taranger J, Lagergård T, Lind L, Sundh V, Zackrisson G, Lowe CU, Blackwelder W, Robbins JB. A placebo-controlled trial of a pertussis-toxoid vaccine. *New England Journal of Medicine*. 1995 Oct 19;333(16):1045-50.

- 
21. Haesebrouck F, Pasmans F, Chiers K, Maes D, Ducatelle R, Decostere A. Efficacy of vaccines against bacterial diseases in swine: what can we expect?. *Veterinary microbiology*. 2004 Jun 3;100(3-4):255-68.
  22. Sell S. How vaccines work: immune effector mechanisms and designer vaccines. *Expert review of vaccines*. 2019 Oct 3;18(10):993-1015.
  23. Rusnak JM, Smith LA. Botulinum neurotoxin vaccines: Past history and recent developments. *Human vaccines*. 2009 Dec 1;5(12):794-805.
  24. Tahamtan A, Charostad J, Shokouh SJ, Barati M. An overview of history, evolution, and manufacturing of various generations of vaccines. *Journal of Archives in Military Medicine*. 2017 Sep 30;5(3).
  25. Payette PJ, Davis HL. History of vaccines and positioning of current trends. *Current Drug Targets-Infectious Disorders*. 2001 Nov 1;1(3):241-7.
  26. Chavda VP, Balar PC, Apostolopoulos V. History of vaccination. In *Advanced Vaccination Technologies for Infectious and Chronic Diseases 2024* Jan 1 (pp. 1-12). Academic Press.
  27. Kotloff KL, Wasserman SS, Losonsky GA, Thomas Jr W, Nichols R, Edelman R, Bridwell M, Monath TP. Safety and immunogenicity of increasing doses of a *Clostridium difficile* toxoid vaccine administered to healthy adults. *Infection and immunity*. 2001 Feb 1;69(2):988-95.
  28. Centers for Disease Control and Prevention (CDC). Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Adults Aged 65 Years and Older-Advisory Committee on Immunization Practices (ACIP), 2012. *MMWR: Morbidity & Mortality Weekly Report*. 2012 Jun 29;61(25).
  29. Middaugh JP. Side effects of diphtheria-tetanus toxoid in adults. *American journal of public health*. 1979 Mar;69(3):246-9.
  30. Bardenheier B, Yusuf H, Schwartz B, Gust D, Barker L, Rodewald L. Are parental vaccine safety concerns associated with receipt of measles-mumps-rubella, diphtheria and tetanus toxoids with acellular pertussis, or hepatitis B vaccines by children?. *Archives of pediatrics & adolescent medicine*. 2004 Jun 1;158(6):569-75.
  31. Gupta S, Pellett S. Recent developments in vaccine design: From live vaccines to recombinant toxin vaccines. *Toxins*. 2023 Sep 8;15(9):563.